DEEP TRACK CAPITAL LP
Q3 2026 Form 13-F
GREENWICH, CONNECTICUT
CIK 0001856083
· CRD 312459
· SEC-registered investment adviser
$6.1B Reported Value Total
DEEP TRACK CAPITAL, LP reports 5 total accounts under management (AUM). There are 5 discretionary accounts valued at $8,373,382,671, and 0 non-discretionary accounts.
Source: Form ADV filed * Note that certain holdings are exempt from Form 13-F reporting, so the AUM totals may be greater than the Form 13-F total.
Private funds (Form ADV)
2 funds
· $8.4B gross asset value
Hedge Fund: $8.4B
Source: Form ADV filed 2026-03-31
Reported value
$6.1B
Quarter over quarter
-7.3%
Holdings
71
Top-10 concentration
43.4%
Key People
Form ADV owners & control persons
David Eric Kroin
MANAGING MEMBER
Nir Salman Messafi
CHIEF OPERATING AND FINANCIAL OFFICER / CHIEF COMPLIANCE OFFICER
Filing Navigation
13F Metrics
Loading 13F Metrics
Q3 2026 13F record
Q3 2026 13F filing summary
| Period of report | September 30, 2026 |
|---|---|
| Filed | November 16, 2026 |
| Form | 13F-HR |
| Reported value | $6.1B |
| Positions | 71 |
| Change in reported value | -10.7% |
| New positions | 18 |
| Exited positions | 13 |
| Position turnover | 36.9% |
| Top-10 concentration | 43.4% |
13F filings by quarter
| Quarter | Positions | Value |
|---|---|---|
|
Q3 2026 13F
Filed Nov 16, 2026
|
71 | $6.1B |
|
Q2 2026 13F
Filed Aug 14, 2026
|
66 | $6.9B |
|
Q1 2026 13F
Filed May 15, 2026
|
62 | $6.1B |
|
Q4 2025 13F
Filed Feb 13, 2026
|
53 | $5.6B |
|
Q3 2025 13F
Filed Nov 14, 2025
|
56 | $3.6B |
|
Q2 2025 13F
Filed Aug 14, 2025
|
65 | $3.1B |
|
Q1 2025 13F
Filed May 15, 2025
|
69 | $3.1B |
|
Q4 2024 13F
Filed Feb 14, 2025
|
61 | $2.7B |
|
Q3 2024 13F
Filed Nov 14, 2024
|
69 | $3.2B |
|
Q2 2024 13F
Filed Aug 14, 2024
|
67 | $3.4B |
|
Q1 2024 13F
Filed May 15, 2024
|
65 | $3.5B |
|
Q4 2023 13F
Filed Feb 14, 2024
|
57 | $3.0B |
|
Q3 2023 13F
Filed Nov 14, 2023
|
62 | $2.6B |
|
Q2 2023 13F
Filed Aug 14, 2023
|
53 | $2.2B |
|
Q1 2023 13F
Filed May 15, 2023
|
54 | $2.4B |
|
Q4 2022 13F
Filed Feb 14, 2023
|
57 | $2.4B |
|
Q3 2022 13F
Filed Nov 14, 2022
|
60 | $2.2B |
|
Q2 2022 13F
Filed Aug 12, 2022
|
49 | $1.5B |
|
Q1 2022 13F
Filed May 16, 2022
|
49 | $1.6B |
|
Q4 2021 13F
Filed Feb 14, 2022
|
49 | $1.4B |
Top 20 holdings · Q3 2026
| # | Holding | Reported value | % of portfolio |
|---|---|---|---|
| 1 | GH GUARDANT HEALTH INC | $500.4M | 8.15% |
| 2 | BMRN BIOMARIN PHARMACEUTICAL INC | $382.5M | 6.23% |
| 3 | IMVT IMMUNOVANT INC | $309.5M | 5.04% |
| 4 | TARS TARSUS PHARMACEUTICALS INC | $299.3M | 4.87% |
| 5 | MANE VERADERMICS INC | $230.3M | 3.75% |
| 6 | VERA VERA THERAPEUTICS INC | $226.0M | 3.68% |
| 7 | PCVX VAXCYTE INC | $199.9M | 3.26% |
| 8 | ALKS ALKERMES PLC | $182.3M | 2.97% |
| 9 | OCUL OCULAR THERAPEUTIX INC | $168.3M | 2.74% |
| 10 | UTHR UNITED THERAPEUTICS CORP DEL | $162.6M | 2.65% |
| 11 | GPCR STRUCTURE THERAPEUTICS INC | $156.4M | 2.55% |
| 12 | GRAL GRAIL INC | $154.7M | 2.52% |
| 13 | INSM INSMED INC | $154.1M | 2.51% |
| 14 | CMPS COMPASS PATHWAYS PLC | $151.3M | 2.46% |
| 15 | GMAB GENMAB A/S | $149.2M | 2.43% |
| 16 | AXSM AXSOME THERAPEUTICS INC. | $147.5M | 2.4% |
| 17 | NRIX NURIX THERAPEUTICS INC | $142.3M | 2.32% |
| 18 | LBRX LB PHARMACEUTICALS INC | $128.7M | 2.1% |
| 19 | TNGX TANGO THERAPEUTICS INC | $112.3M | 1.83% |
| 20 | MAZE MAZE THERAPEUTICS INC | $111.0M | 1.81% |
Values as reported on the Q3 2026 Form 13F. Every position is in the holdings table below.